Anavex Life Scie - AVXL STOCK NEWS

Anavex Life Sciences Corp. (Nasdaq: AVXL) will present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:40 AM (ET). The company specializes in developing therapeutics for neurodegenerative disorders, including Alzheimer’s, Parkinson’s, and Rett syndrome. Anavex's lead drug candidate, ANAVEX®2-73, has shown promise in clinical trials, demonstrating potential benefits for both Alzheimer’s and Parkinson’s disease. The live audio webcast of the presentation will be available on the company’s website and will be accessible for 30 days post-event.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U. Missling, PhD, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast of the on-demand presentation will be available starting September 13 at 7:00 A.M. (ET) through their website and the conference platform. Anavex specializes in therapeutics for neurodegenerative disorders, having successfully completed clinical trials for its lead drug candidate ANAVEX®2-73, designed for Alzheimer’s and Parkinson’s diseases.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the publication of preclinical data on ANAVEX®2-73 (blarcamesine) for treating Fragile X Syndrome in Scientific Reports. The study demonstrated the drug's ability to reverse hyperactivity, restore associative learning, and reduce anxiety in Fmr1 knockout mice. Positron emission tomography confirmed dose-dependent receptor occupancy. These findings pave the way for a Phase 2/3 clinical trial, potentially expanding treatment options for the 62,500 Fragile X patients in the US.

Anavex Life Sciences Corp. (Nasdaq: AVXL) reported promising developments in its late-stage clinical trials for ANAVEX®2-73 (blarcamesine). A total of 509 patients have been enrolled in the Phase 2b/3 trial for Alzheimer’s disease, exceeding enrollment targets. The company holds a strong cash position of $157.6 million. However, the net loss for the quarter totaled $10.2 million, or $0.14 per share, which is an increase from $6.5 million in the same quarter last year. Upcoming topline data releases in 2H 2021 for Rett syndrome and 2H 2022 for Alzheimer’s disease are anticipated.

Anavex Life Sciences Corp. (Nasdaq: AVXL) will announce its financial results for the fiscal quarter ending June 30, 2021, on August 12, 2021, at 4:30 PM EDT. A conference call will follow, allowing management to discuss financial results and strategies for growth. Anavex specializes in developing therapeutics for neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Parkinson's diseases. The company's lead drug, ANAVEX®2-73, has shown promise in clinical trials.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced participation by CEO Christopher U. Missling, PhD, in the BTIG Virtual Biotechnology Conference 2021 on August 10, 2021, at 9:30 a.m. EDT. The conference will focus on the company's development of therapeutics for neurodegenerative disorders like Alzheimer's and Parkinson's diseases. Anavex's lead drug, ANAVEX®2-73, showed promise in clinical trials and targets sigma-1 and muscarinic receptors to restore cellular balance. A webcast of the event will be available on Anavex's website under the Investors section.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced promising data indicating that ANAVEX^®2-73 can prevent cognitive decline associated with Alzheimer's disease. In preclinical studies, the drug showed significant protection against Aβ_25-35-induced cognitive impairments. The company plans to initiate a Phase 3 trial focusing on prevention in at-risk patients. Previously, clinical studies demonstrated cognitive improvements in Alzheimer's patients after treatment with ANAVEX^®2-73 over 57 weeks. These advancements highlight the drug's potential in addressing significant unmet needs in neurodegenerative therapies.

Anavex Life Sciences Corp. (AVXL) announced promising results from its Phase 2 trial of ANAVEX®2-73 for treating Parkinson’s disease dementia. The treatment significantly increased the expression of the SIGMAR1 mRNA biomarker, correlating with improvements in cognitive and clinical efficacy endpoints, including a 14.51-point reduction in the MDS-UPDRS Total score (p = 0.034) compared to placebo. The study supports the regulatory pathway for ANAVEX®2-73 as a potential therapeutic option for Parkinson's disease. The findings will be submitted to the FDA to seek further regulatory guidance.

Anavex Life Sciences Corp. (Nasdaq: AVXL) has successfully closed a registered direct offering with Deep Track Capital, issuing 2,380,953 shares at $21.00 per share, raising approximately $50 million before fees. The funds are earmarked for advancing its drug pipeline and general corporate purposes. The offering is made under the effective shelf registration statement with the SEC. Anavex is focused on developing therapeutics for neurodegenerative disorders, including its lead candidate, ANAVEX®2-73, which has shown promise in clinical trials for Alzheimer’s and Parkinson’s diseases.